Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

By G. Lenz, R. Davis, Vu N. Ngo, L. Lam, T. George, George W. Wright, S. Dave, Hong Zhao, Weihong Xu, Andreas Rosenwald and 12 more. Science, 2008

886 citations recorded by the source corpus.

Subfields: Cancer Research, Immunology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/4f51ca3cc681e27fce3aa917f3e093bd0d8b3715

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. M. Karin
2. Joseph A. DiDonato
3. F. Mercurio
4. R. Jove
5. Hua Yu
6. D. Pardoll
7. David Baltimore
8. Y. Ben‐Neriah

In Immunology

1. M. Karin
2. Y. Ben‐Neriah
3. David Baltimore
4. Joseph A. DiDonato
5. Hua Yu
6. F. Mercurio
7. R. Jove
8. M. Lenardo

In Pathology and Forensic Medicine

1. D. Pardoll
2. Hua Yu
3. M. Karin
4. R. Jove
5. Benjamin L. Ebert
6. Mark I. McCarthy
7. Siddhartha Jaiswal

Citations in the corpus

• Persistently-activated Stat3 maintains constitutive NF-κB activity in tumors (2009, positive): “…with only a few exceptions, such as lymphoid tumors, where activating mutations of upstream IKK activators such as CARD11 have been identified (Lenz et al., 2008; Pomerantz et al., 2002), IKK is not often continuously activated in cultured cancer cells but rather is inducible by…”
• Frequent mutation of histone modifying genes in non-Hodgkin lymphoma (2011, background): “For example, 85–90% of FL and 30–40% of GCB DLBCL cases(3,4) harbour t(14;18)(q32;q21), which results in deregulated expression of the BCL2 oncoprotein.”
• Inflammation meets cancer, with NF-κB as the matchmaker (2011, background): “Activating mutations in CARD11 (which encodes Carma-1) have been detected in activated B cell–like diffuse large B cell lymphoma, another B cell malignanc”
• Age-related clonal hematopoiesis associated with adverse outcomes. (2014, positive): “Sequencing studies have identified a set of recurrent mutations in several types of hematologic cancers.(12-24) However, the frequency of these somatic mutations in the general population is unknown.”
• The Role of Resveratrol in Cancer Therapy (2017, background): “Active NF-κB drives the expression of a plethora of genes that guard against apoptotic cell death and maintain cell proliferation [158].”
• 30 years of NF-κB: a blossoming of relevance to human pathobiology (2017, positive): “Introducing the mutant CARD11 into lymphoma cell lines constitutively induces NF-κB (Lenz et al., 2008) (see below).”